Workflow
Moderna(MRNA) - 2024 Q4 - Earnings Call Transcript
MRNAModerna(MRNA)2025-02-14 17:07
Filings
Slide

Financial Data and Key Metrics Changes - In 2024, the company recorded total revenue of 3.2billion,a533.2 billion, a 53% decline from 2023, primarily due to lower product sales [23][27] - The net loss for the year was 3.6 billion, compared to a loss of 4.7billionin2023,withalosspershareof4.7 billion in 2023, with a loss per share of 9.28 compared to 12.33inthepriorperiod[27]−Cash,cashequivalents,andinvestmentstotaled12.33 in the prior period [27] - Cash, cash equivalents, and investments totaled 9.5 billion at the end of the quarter, up from 9.2billionattheendofthethirdquarter[22]BusinessLineDataandKeyMetricsChanges−ForQ42024,netproductsaleswere9.2 billion at the end of the third quarter [22] Business Line Data and Key Metrics Changes - For Q4 2024, net product sales were 0.9 billion, with 0.2billionintheUnitedStatesand0.2 billion in the United States and 0.7 billion outside the United States [13] - Full-year net product sales were 3.1billion,withU.S.salesat3.1 billion, with U.S. sales at 1.7 billion, benefiting from a favorable adjustment related to a prior period return reserve reversal [13][14] - The majority of sales were from Spikevax, while mRESVIA generated only 25millioninsalesforthefullyear[15]MarketDataandKeyMetricsChanges−Internationalsaleswereloweryear−over−year,reflectingtheongoingphase−outofadvancedpurchaseagreements[16]−ThecompanyobservedsignsofstabilizationintheCOVIDmarket,believingitwillremaindurableovertimedespitelowervaccinationratesandincreasedcompetition[14]CompanyStrategyandDevelopmentDirection−Thecompanyannouncedafocuson10high−valueprogramsexpectedtodrivesalesgrowthanddiversificationfromCOVIDoverthenextthreeyears[8]−Thestrategicresizinginitiativelaunchedin2023aimstooptimizethemanufacturingfootprintandalignwiththetransitiontoaseasonalendemicmarket[18]−Thecompanyplanstoreducecashcoststoanestimated25 million in sales for the full year [15] Market Data and Key Metrics Changes - International sales were lower year-over-year, reflecting the ongoing phase-out of advanced purchase agreements [16] - The company observed signs of stabilization in the COVID market, believing it will remain durable over time despite lower vaccination rates and increased competition [14] Company Strategy and Development Direction - The company announced a focus on 10 high-value programs expected to drive sales growth and diversification from COVID over the next three years [8] - The strategic resizing initiative launched in 2023 aims to optimize the manufacturing footprint and align with the transition to a seasonal endemic market [18] - The company plans to reduce cash costs to an estimated 5.5 billion in 2025 and 5billionin2026,aimingforbreakevenonacash−costbasisnolaterthan2028[48][49]Management′sCommentsonOperatingEnvironmentandFutureOutlook−ManagementexpressedconfidenceinthedurabilityoftheCOVIDmarketandthepotentialforgrowthfromnewproductapprovals[14][31]−Thecompanyanticipatestotalrevenuein2025tobeintherangeof5 billion in 2026, aiming for breakeven on a cash-cost basis no later than 2028 [48][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of the COVID market and the potential for growth from new product approvals [14][31] - The company anticipates total revenue in 2025 to be in the range of 1.5 billion to 2.5billion,reflectinguncertaintiesinvaccinationratesandmarketcompetition[31]−Managementemphasizedtheimportanceofcostmanagementandoperationalefficienciestopositionthecompanyforlong−termsuccess[35]OtherImportantInformation−Thecompanyreportedasignificantreductioninoperatingexpensesin2024,withcostsdecliningfrom2.5 billion, reflecting uncertainties in vaccination rates and market competition [31] - Management emphasized the importance of cost management and operational efficiencies to position the company for long-term success [35] Other Important Information - The company reported a significant reduction in operating expenses in 2024, with costs declining from 11.1 billion to 7.2 billion [28] - R&D expenses for the year were 4.5 billion, down 6% from 2023, primarily due to lower clinical trial and manufacturing costs [24] Q&A Session Summary Question: Can you help us understand the breakdown of the R&D spend across your program? - Management indicated there is flexibility to reduce R&D spending further, with guidance of $4.1 billion for 2025 and potential reductions by 2027 [55] Question: What would it take for the FDA to remove the clinical hold on Norovirus? - Management stated that the FDA needs time to review submitted materials, and any decision will depend on their assessment [67] Question: Should we still expect the final readout for CMV in the first half of 2025? - Management confirmed that they still expect the final results for the CMV trial in 2025, although specific timing was not provided [66] Question: Can you clarify the approval requirements for the COVID-flu combo vaccine? - Management confirmed that efficacy for the COVID component has been demonstrated, but efficacy for the flu component is still required [88] Question: What variables would affect the 2025 revenue guidance? - Management noted that vaccination rates, market share, and competitive dynamics would influence whether they land at the low or high end of their guidance [133]